SCHEDULE: Intracoastal Capital Discloses 4.99% Stake in Bionano Genomics

Sentiment:

Beneficial Ownership Report 19 September 2025 4:34 PM

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a passive beneficial ownership of 4.99% in Bionano Genomics, Inc. common stock.

Capital raiseThe beneficial ownership stems from a Securities Purchase Agreement (SPA) executed on September 16, 2025, with Bionano Genomics, Inc.The SPA involved the issuance of 525,000 shares of Common Stock to Intracoastal at the closing of the transaction, along with warrants (Intracoastal Warrant 1, 2, and 3) for additional shares.As of September 19, 2025, 4,925,000 shares of Common Stock were issued at the closing of the transaction contemplated by the SPA, and 508,415 shares were issued to Intracoastal upon exercise of Intracoastal Warrant 1.

Summary

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC are the Reporting Persons.
Beneficial ownership totals 508,415 shares of Bionano Genomics, Inc. Common Stock.
This ownership represents 4.99% of the company's outstanding Common Stock.
The shares are issuable upon the exercise of Intracoastal Warrant 1.
Warrants held by Intracoastal Capital include blocker provisions that prevent beneficial ownership from exceeding 4.99% of the Common Stock.
The filing is a Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, indicating a passive investment. It does not inherently convey positive or negative sentiment about the company's performance or prospects, but rather the investor's position.

Positives

Continued investment by Intracoastal Capital, suggesting ongoing confidence in Bionano Genomics.
The passive nature of the investment (Schedule 13G) indicates no immediate intent to influence company control, which can provide stability.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: Provides transparency regarding a significant passive investor's stake, which could be viewed as a vote of confidence in the company.
Company Management: Awareness of a significant passive shareholder holding just under the 5% threshold, indicating a notable investor interest without active control intentions.

Key Dates

Date	Description
2025-09-09	Bionano Genomics, Inc. reported 4,755,265 shares of Common Stock outstanding.
2025-09-16	Date of event requiring the filing, marked by the execution of a Securities Purchase Agreement (SPA) with Bionano Genomics, Inc.
2025-09-18	Bionano Genomics, Inc. filed a Form 8-K disclosing the Securities Purchase Agreement.
2025-09-19	As of the close of business, Reporting Persons were deemed to have beneficial ownership of 508,415 shares.

Recommendation

hold

This Schedule 13G filing primarily serves as a disclosure of a passive ownership stake by Intracoastal Capital and its principals. It does not contain new financial performance data, strategic shifts, or operational updates that would warrant a change in investment recommendation. The 4.99% stake, while significant, is below the threshold for active influence and is consistent with a long-term, passive investment strategy. Investors should 'hold' and await further operational or financial news for a more comprehensive assessment.

Keywords

Bionano Genomics, BNGO, Intracoastal Capital, Mitchell Kopin, Daniel Asher, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.